Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genomic Research Center, |
RCV000785178 | SCV000923745 | uncertain significance | Usher syndrome type 2A | 2019-01-01 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000785178 | SCV001806337 | uncertain significance | Usher syndrome type 2A | 2021-07-22 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001578969 | SCV001806338 | uncertain significance | Retinitis pigmentosa 39 | 2021-07-22 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002535724 | SCV003458549 | likely pathogenic | not provided | 2023-08-21 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 634644). This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 524 of the USH2A protein (p.Ala524Val). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with clinical features of Usher syndrome and/or retinitis pigmentosa (PMID: 30902645, 34148116). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on USH2A protein function. This variant disrupts the p.Ala524 amino acid residue in USH2A. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 30902645, 33576794). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
Baylor Genetics | RCV001578969 | SCV004208325 | likely pathogenic | Retinitis pigmentosa 39 | 2024-02-28 | criteria provided, single submitter | clinical testing |